OncLive and Targeted Oncology: Drug yields long-lasting benefits to treat PEComa tumors
OncLive and Targeted Oncology covered research presented by the University of Cincinnati's Thomas Herzog that found patients with perivascular epithelioid sarcoma (PEComa) of gynecologic or peritoneal origin experienced rapid, durable responses when treated with the drug nab-sirolimus.
At the 2024 SGO Annual Meeting on Women's Cancer, Herzog presented results from a subgroup analysis of the phase 2 AMPECT trial. Nab-sirolimus is the first and only FDA-approved treatment for advanced PEComa.
"The median time to response was extremely fast, about 1.4 months, and the duration of response was a little over 36 months," Herzog, MD, a University of Cincinnati Cancer Center member, the Paul and Carolyn Flory Professor in Gynecologic Oncology in the UC College of Medicine and director of UC Health’s Gynecologic Cancer Disease Center, told Targeted Oncology. "It is important to remember these responses occur often rapidly, and they are quite durable."
Watch the Targeted Oncology video.
Featured photo at top of Thomas Herzog. Photo provided.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.